Pyoderma gangrenosum
Pyoderma gangrenosum är en sällsynt, inflammatorisk hudsjukdom där smärtsamma pustler eller knölar blir till sår som gradvis växer. Pyoderma gangrenosum är inte smittsamt. Behandlingar kan innefatta kortikosteroider, ciklosporin eller olika monoklonala antikroppar. Även om det kan påverka människor i alla åldrar, drabbar det mestadels människor i 40- och 50-årsåldern.
☆ I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
På benet av en person med ulcerös kolit.
References
Pyoderma gangrenosum är en sällsynt hudsjukdom som orsakar smärtsamma sår med röda eller lila kanter. Det är klassificerat som en inflammatorisk sjukdom och ingår i en grupp som kallas neutrofila dermatoser. Orsaken till pyoderma gangrenosum är komplex och involverar problem med både medfödd och adaptiv immunitet hos personer som är genetiskt benägna. Nyligen har forskare fokuserat på hårsäcken som en potentiell utgångspunkt för sjukdomen.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum är en sällsynt hudsjukdom som orsakar extremt smärtsamma sår. Även om vi inte helt förstår dess orsak, vet vi att det innebär ökad aktivitet hos vissa immunceller. Att behandla sjukdomen är fortfarande inte lätt. Vi har olika läkemedel som hämmar immunförsvaret eller modifierar dess aktivitet. Vid sidan av dessa fokuserar vi också på att behandla såren och hantera smärta. Kortikosteroider och ciklosporin är ofta förstahandsvalet för behandling, men på senare tid har det skett mer forskning om att använda biologiska terapier som TNF-α-hämmare. Dessa biologiska läkemedel föredras alltmer, särskilt hos patienter med andra inflammatoriska tillstånd, och de används tidigare i sjukdomsprocessen.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
